Bayer is an agrochemicals, polymers and healthcare company with its activities in four subgroups of largely independent operations: Bayer HealthCare, Bayer CropScience, Bayer MaterialScience and Bayer Business Services.
Bayer HealthCare focuses on consumer health care businesses to capitalise on growth opportunities, particularly in over-the-counter medicines, self-testing systems and animal health products. Bayer CropScience is a supplier of crop protection, seeds, biotechnology and non-agricultural pest control. Bayer MaterialScience is a major plastics producer and Bayer Business Services is the group's IT-based competence centre providing business, administrative and scientific services.
Bayer's business strategy will continue to focus on “fast-growing innovation-driven” health care, nutrition and high-tech materials businesses. It will strategically align itself into attractive markets and concentrate on its core competencies.
Bayer aims to invest more intensively in growth areas and innovative technologies in order to achieve a leadership role. It will also go ahead with cost-containment and efficiency-improvement efforts in order to further increase the company's value over the long term.
Download the The ICIS Top 100 Chemical Companies listing here
Chairman: Marijn Dekkers
Chief financial officer: Werner Baumann
Member (strategy and HR): Richard Pott
Chairman of the supervisory board: Manfred Schneider
Deputy chairman of the supervisory board: Thomans de Win
Bayer AG Werk Leverkusen 51368 Leverkusen Germany
Tel: +49 0 214 301 Fax: +49 0 214 308
Bayer AG is an agrochemicals, polymers and healthcare group. The Bayer’s roots date back to 1863 where Friedrich Bayer and Johann Friedrich Weskott opened a modest dye works by the name Friedr. Bayer & Co. in Wuppertal-Barmen. The company's headquarters were moved in 1912 to Leverkusen, Germany, on the banks of the Rhine, where it has remained to this day.
More about Bayer AG Structure
Bayer's business strategy will continue to focus on “fast-growing innovation-driven” health care, nutrition and high-tech materials businesses. It will strategically align itself into what Bayer calls “attractive markets” and concentrate on its core competencies. It aims to invest more intensively in growth areas and innovative technologies in order to achieve a leadership role. It will also go ahead with cost-containment and efficiency-improvement efforts in order to further increase the company's value over the long term. (Edited from: “Chairman's letter” and Annual Report). ICIS also provides you with key financial data listed in table form.
More about Bayer AG Strategy & Financial Highlights
Get news on Bayer AG plus the latest chemical news, information, data, market movements and analysis
in one place with ICIS news
Find details on other chemical companies and suppliers with
ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.
Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database
INSIGHT: China may see major ethylene shortfall by 2019
"At $50-90/bbl for Brent, UBS estimates the internal rate of return (IRR) for China CTO/MTO projects range from 5-10% – mostly too low to justify inve
VIDEO: ICIS Special Report: Innovation is key to success